Cite

HARVARD Citation

    Devasenapathy, N. et al. (2023). Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet. pp. 13-25. [Online]. 
  
Back to record